Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A.

MLA

Parry, Christopher M., et al. “Clinically and Microbiologically Derived Azithromycin Susceptibility Breakpoints for Salmonella Enterica Serovars Typhi and Paratyphi A.” Antimicrobial Agents and Chemotherapy, vol. 59, no. 5, May 2015, pp. 2756–64. EBSCOhost, https://doi.org/10.1128/AAC.04729-14.

APA

Parry, C. M., Thieu, N. T. V., Dolecek, C., Karkey, A., Gupta, R., Turner, P., Dance, D., Maude, R. R., Ha, V., Tran, C. N., Thi, P. L., Be, B. P. V., Phi, L. T. T., Ngoc, R. N., Ghose, A., Dongol, S., Campbell, J. I., Thanh, D. P., Thanh, T. H., … Baker, S. (2015). Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. Antimicrobial Agents and Chemotherapy, 59(5), 2756–2764. https://doi.org/10.1128/AAC.04729-14

Chicago

Parry, Christopher M, Nga Tran Vu Thieu, Christiane Dolecek, Abhilasha Karkey, Ruchi Gupta, Paul Turner, David Dance, et al. 2015. “Clinically and Microbiologically Derived Azithromycin Susceptibility Breakpoints for Salmonella Enterica Serovars Typhi and Paratyphi A.” Antimicrobial Agents and Chemotherapy 59 (5): 2756–64. doi:10.1128/AAC.04729-14.